AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03630146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPeer2Peer program
Description: In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
Study NCT03630146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: The control group will receive standard care but without the iPeer2Peer Program.
Study NCT03842267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin 50mg
Description: * The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day
Study NCT03842267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin Placebo
Description: * The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* - The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day
Study NCT03421886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerodentis system
Description: The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
Study NCT03421886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invisalign clear aligner system
Description: Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
Study NCT03679104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of mucosotomy using endoscopic clips
Description: Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
Study NCT03679104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of mucosotomy using OverStitch™ suturing device
Description: Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
Study NCT00535418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT02789605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacilor
Description: Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
Study NCT02789605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
Study NCT04249713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Interleukin 17 Receptor A Antagonist
Study NCT04433078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100 MG Tablet
Study NCT04433078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet
Study NCT02961569 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: sputum collection for acid fast bacilli
Description: spontaneous or post fiberoptic bronchoscopy sputa
Study NCT01164098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Induction therapy
Study NCT01890811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boost High Protein
Description: Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
Study NCT01533441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K2
Description: 4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
Study NCT01533441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2
Description: 4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
Study NCT01624935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy
Description: interpersonal psychotherapy
Study NCT01624935 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interpersonal psychotherapy
Description: interpersonal psychotherapy
Study NCT01871025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital and home exercise training
Description: Hospital exercise training (aerobic and strength) followed by exercise training
Study NCT01871025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-pegylated liposomal doxorubicin
Description: 20 mg/m2, i.V. 18 times weekly
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel 80mg/m² 18 times weekly
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80mg/m² 18 times weekly
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 150mg/m² every 2 weeks for 3 cycles.
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 2000 mg/m² every 2 weeks for 3 cycles.
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
Study NCT02819505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Study NCT02125344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
Study NCT02819505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03388892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)
Description: Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
Study NCT03941691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully Absorbable VSD Occlusion System
Description: Under echocardiography guided treatment of VSD with a novel fully degradable clolsure system
Study NCT03941691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VSD Occluder
Description: Under echocardiography guided treatment of VSD with commercially available occluder.
Study NCT01478893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-068
Description: Sub-cutaneous injection, multiple dose
Study NCT01478893 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sub-cutaneous injection, multiple dose
Study NCT03388892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain Balloon
Description: Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
Study NCT03975153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: guselkumab
Description: Treatment at the FDA-approved psoriasis dosing for 20 weeks
Study NCT00609752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
Study NCT00609752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alicalm (polymeric liquid formula)
Description: Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks.
Study NCT03067792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil, irinotecan and leucovorin
Description: In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
Study NCT03067792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Description: In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
Study NCT04149496 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: in vitro maturation of oocytes
Description: Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
Study NCT04473781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interstitial Radiation Therapy
Description: Undergo interstitial brachytherapy
Study NCT01584258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatectomy
Description: Radical prostatectomy: performed open, laparoscopically or using a robotically assisted laparoscopic approach.
Study NCT01584258 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated Prostate Radiotherapy
Description: Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions
Study NCT01584258 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate SBRT
Description: Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
Study NCT03807115 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of stroke mobility guidelines
Description: Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
Study NCT04599049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: six sessions of online classes and virtual training day camps through Zoom in two days
Description: The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively.
Study NCT01511432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir formulation A
Description: A single 1125-mg dose administered orally
Study NCT01511432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation B
Description: A single 1125-mg dose administered orally
Study NCT01511432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation C
Description: A single 1125-mg dose administered orally
Study NCT01511432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation D
Description: A single 1125-mg dose administered orally
Study NCT00895648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² iv infusion every 3 weeks for 3 cycles
Study NCT00895648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² iv infusion every 3 weeks for 3 cycles
Study NCT00276549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02465346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSU-based stroke management
Description: Prehospital stroke treatment with a mobile stroke unit
Study NCT02465346 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control stroke management
Description: Conventional stroke management
Study NCT02196987 — intervention group
Intervention type: OTHER
Intervention: Urination during urethral catheterisation
Description: Requesting the patient to urinate while inserting urethral catheter
Study NCT02196987 — intervention group
Intervention type: OTHER
Intervention: Urethral catheterisation, without further guidance
Description: Lying, inserting urethral catheter, without further guidance from health care professional
Study NCT04266106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SuperBio probiotic
Description: One capsule po BID for 28 days
Study NCT04266106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule po BID for 28 days
Study NCT01809925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium fiber 6.8g
Description: Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
Study NCT04563702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1
Description: non replicating Ad5 adjuvanted oral tableted vaccine
Study NCT01809925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
Study NCT01608282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPEN website
Description: The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
Study NCT01889888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submucosal injection of ADRC
Description: Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
Study NCT04511819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod oral tablet
Description: Losmapimod will be administered with food when possible.
Study NCT04511819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be administered with food when possible.
Study NCT02297113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh blade
Description: conventional endotracheal intubation
Study NCT02297113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Study NCT03215043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriocitrin
Description: The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
Study NCT04929613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Resilience Training
Description: 2.5-day intensive MBRT training sessions.
Study NCT01033487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral inhaled formulation, single dose
Study NCT01033487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active comparator
Description: oral inhaled formulation, single dose
Study NCT01033487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose PF-03635659
Description: oral inhaled formulation, single dose, low dose
Study NCT01033487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid Dose PF-03635659
Description: oral inhaled formulation, single dose, mid dose
Study NCT01033487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose PF-03635659
Description: oral inhaled formulation, single dose, high dose
Study NCT03355794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Oral capsule or liquid formula
Study NCT03355794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Oral tablets or dispersible tablets
Study NCT02701192 — intervention group
Intervention type: OTHER
Intervention: Coccygectomy
Description: Patient receiving coccygectomy surgery.